Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model

Experimental Lung Research

Volumn 36, Issue 10, 2010, Pages 602-614

  Wuyts, W A ^a   Willems, S ^a   Vos, R ^a   Vanaudenaerde, B M ^a   De Vleeschauwer, S I ^a   Rinaldi, M ^a   Vanhooren, H M ^a   Geudens, N ^a   Verleden, S E ^a   Demedts, M G ^a   Thomeer, M ^a   Verbeken, E K ^a   Verleden, G M ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Azithromycin; Bleomycin; Idiopathic pulmonary fibrosis; Inflammation; Interleukin; Lung function; Neutrophils

Indexed keywords

AZITHROMYCIN; BLEOMYCIN; COLLAGEN TYPE 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 21; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; INNATE IMMUNITY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MACROPHAGE; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPINDLE CELL; T LYMPHOCYTE ACTIVATION; TH17 CELL; TH2 CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BIOLOGICAL MARKERS; BLEOMYCIN; BODY WEIGHT; BRONCHOALVEOLAR LAVAGE FLUID; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; IMMUNITY, INNATE; LEUKOCYTE COUNT; LUNG; MICE; MICE, INBRED C57BL; RESPIRATORY FUNCTION TESTS;

EID: 78149251501     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2010.492895     Document Type: Article

References (39)

1. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Id-iopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS) and the European Respiratory Society (ERS) was adopted by the ATS board of directors and by the ERS Executive Committee. Am J Respir Crit Care Med. 2001;165:277-304.
2. American Thoracic Society: Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS) and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161:646-664.
3. Maher TM, Wells AU, Laurent GJ: Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J. 2007;30:835-839.
4. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, MacNee W, Thomeer M, Wallaert B, Laurent F, Nicholson AG, Verbeken EK, Verschakelen J, Flower CD, Capron F, Petruzzelli S, De VP, Van Den Bosch JM, Rodriguez-Becerra E, Corvasce G, Lankhorst I, Sardina M, Montanari M: High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353:2229-2242.
5. Verleden GM, Dupont LJ: Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004;77:1465-1467.
6. Gottlieb J, Szangolies J, Koehnlein T, Golpon H, Simon A, Welte T: Long-term azithromycin for bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2008;85:36-41.
7. Shitrit D, Bendayan D, Gidon S, Saute M, Bakal I, Kramer MR: Long-term azithromycin use for treatment of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 2005;24:1440-1443.
8. Porhownik NR, Batobara W, Kepron W, Unruh HW, Bshouty Z: Effect of maintenance azithromycin on established bron-chiolitis obliterans syndrome in lung transplant patients. Can Respir J. 2008;15:199-202.
9. Vanaudenaerde BM, Meyts I, Vos R, Geudens N, De WW, Verbeken EK, Van Raemdonck DE, Dupont LJ, Verleden GM: A dichotomy in bronchiolitis obliterans syndrome after lung transplantation revealed by azithromycin therapy. Eur Respir J. 2008;32:832-843.
10. Vanaudenaerde BM, Vos R, Meyts I, De Vleeschauwer SI, Verleden SE, Widyastuti-Willems A, Wuyts WA, Van Raemdonck DE, Hoet PH, Dupont LJ, Nemery B, Verleden GM: Macrolide therapy targets a specific phenotype in respiratory medicine: from clinical experience to basic science and back. Inflamm Allergy Drug Targets. 2008;7:279-287.
11. Keane MP, Belperio JA, Moore TA, Moore BB, Arenberg DA, Smith RE, Burdick MD, Kunkel SL, Strieter RM: Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J Immunol. 1999;162:5511-5518.
12. McAnulty RJ, Laurent GJ: Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol. 1995;3:96-107.
13. Russo RC, Guabiraba R, Garcia CC, Barcelos LS, Roffe E, Souza AL, Amaral FA, Cisalpino D, Cassali GD, Doni A, Bertini R, Teixeira MM. Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol. 2009;40:410-421.
14. Veeraraghavan S, Latsi PI, Wells AU, Pantelidis P, Nicholson AG, Colby TV, Haslam PL, Renzoni EA, du Bois RM. BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. Eur Respir J. 2003;22:239-244.
15. Lynch JP 3rd, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM: Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev Respir Dis. 1992;145:1433-1439.
16. Kinder BW, Brown KK, Schwarz MI, Ix JH, Kervitsky A, King TE: Baseline BAL neutrophilia predicts early mortality in idio-pathic pulmonary fibrosis. Chest. 2008;133:226-232.
17. Vos R, Vanaudenaerde BM, De Vleeschauwer SI, Willems-Widyastuti A, Van Raemdonck DE, Dupont LJ, Verleden GM. Circulating and intrapulmonary C-reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome. J Heart Lung Transplant. 2009;28:799-807.
18. Gauldie J, Kolb M: Animal models of pulmonary fibrosis: how far from effective reality? Am J Physiol Lung Cell Mol Physiol. 2008;294:L151.
19. Iwakura Y, Ishigame H: The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116:1218-1222.
20. Linden A, Laan M, Anderson GP. Neutrophils, interleukin-17A and lung disease. Eur Respir J. 2005;25:159-172.
21. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, Meyts I, Bullens DM, Reynders V, Wuyts WA, Van Raemdonck DE, Dupont LJ, Verleden GM: The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2008;8:1911-1920.
22. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raem-donck DE: Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174: 566-570.
23. Geudens N, Timmermans L, Vanhooren H, Vanaudenaerde BM, Vos R, Van De WC, Verleden GM, Verbeken E, Lerut T, Van Raemdonck DE: Azithromycin reduces airway inflammation in a murine model of lung ischaemia reperfusion injury. Transpl Int. 2008;21:688-695.
24. Thrall RS, Swendsen CL, Shannon TH, Kennedy CA, Frederick DS, Grunze MF, Sulavik SB: Correlation of changes in pulmonary surfactant phospholipids with compliance in bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis. 1987;136:113-118.
25. Vanoirbeek JA, Rinaldi M, De Vooght V, Haenen S, Bobic S, Gayan-Ramirez G, Hoet PH, Verbeken EK, Decramer M, Nemery B, Janssens W: Noninvasive and invasive pulmonary function in mpuse models of obstructive and restrictive respiratory diseases. Am J Respir Cell Mol Biol. 2010;42: 96-104.
26. Vanaudenaerde BM, Wuyts WA, Geudens N, Dupont LJ, Schoofs K, Smeets S, Van Raemdonck DE, Verleden GM: Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells. Am J Transplant. 2007;7:76-82.
27. Murphy DM, Forrest IA, Corris PA, Johnson GE, Small T, Jones D, Fisher AJ, Egan JJ, Cawston TE, Lordan JL, Ward C: Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant. 2008;27:1210-1216.
28. Murphy DM, Forrest IA, Ward C, Corris PA, Johnson GE, Jones D, Fisher AJ, Egan JJ, Cawston TE, Lordan JL: Effect of azithromycin on primary bronchial epithelial cells derived from stable lung allografts. Thorax. 2007;62:834.
29. Jaffe A, Bush A: Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol. 2001;31:464-473.
30. Ikeda H, Sunazuka T, Suzuki H, Hamasaki Y, Yamazaki S, Omura S, Hatamochi A: EM703, the new derivative of erythromycin, inhibits transcription of type I collagen in normal and scleroderma fibroblasts. J Dermatol Sci. 2008;49:195-205.
31. Li YJ, Azuma A, Usuki J, Abe S, Matsuda K, Sunazuka T, Shimizu T, Hirata Y, Inagaki H, Kawada T, Takahashi S, Kudoh S, Omura S: EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts. Respir Res. 2006;7:16.
32. Verleden GM, Vanaudenaerde BM, Dupont LJ, Van Raemdonck DE: Azithromycin reduces airway neutrophilia and IL-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med. 2006;174:566-570.
33. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199-210.
34. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R: Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83:111-119.
35. Saito F, Tasaka S, Inoue K, Miyamoto K, Nakano Y, Ogawa Y, Yamada W, Shiraishi Y, Hasegawa N, Fujishima S, Takano H, Ishizaka A: Role of interleukin-6 in bleomycin-induced lung inflammatory changes in mice. Am J Respir Cell Mol Biol. 2008;38:566-571.
36. Chua F, Gauldie J, Laurent GJ: Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol. 2005;33:9-13.
37. Simler NR, Howell DC, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, Chambers RC, Egan JJ: The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Respir J. 2002;19:1124-1127.
38. Fujita M, Mizuta Y, Ikegame S, Ouchi H, Ye Q, Harada E, Inoshima I, Yoshimi M, Watanabe K, Nakanishi Y: Biphasic effects of free radical scavengers against bleomycin-induced pulmonary fibrosis. Pulm Pharmacol Ther. 2008;21:805-811.
39. Crokaert F, Hubloux A, Cauchie P: A Phase I Determination of azithromycin in plasma during a 6-week period in normal volunteers after a standard dose of 500mg once daily for 3 days. Clin Drug Investig. 1998;16:161-166.